All Videos

Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.

Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

Panelists discuss how generalized pustular psoriasis (GPP) profoundly impacts patients’ quality of life through physical pain, psychological distress, social isolation, and functional limitations, necessitating comprehensive support systems that address both medical management and psychosocial well-being.

Panelists discuss how the diagnosis and management of generalized pustular psoriasis present significant challenges due to its rarity, complex presentation, potentially life-threatening complications, limited treatment options, and the need for multidisciplinary care approaches.

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.

Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.

Lisa Swanson, MD, FAAD, discusses how caregivers play a crucial role in ensuring successful long-term AD management by providing daily support, monitoring treatment adherence, and offering emotional support, while dermatologists can better support them through education, clear communication, and collaborative care strategies.

Lisa Swanson, MD, FAAD, discusses how current treatment options for this age group fall short in terms of disease control, safety, and ease of use, while highlighting emerging options that promise better efficacy, fewer side effects, and greater convenience.

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

An expert discusses initial thoughts on the case, including the risk category the patient would fall into based on the characteristics of their lesion, outlines the treatment guidelines for melanoma based on their risk, and suggests the frequency of surveillance visits solely based on their traditional risk classification.

Panelists discuss how unique characteristics of different JAK inhibitors, including selectivity profiles, administration routes, and clinical efficacy data, inform treatment selection in real-world practice.

Panelists discuss how inhibition of IL-17 in psoriasis treatment significantly improves quality of life by reducing inflammation, skin lesions, itching, and pain. Patients report better psychological well-being, increased social confidence, and improved daily functioning as inflammatory pathways are interrupted.

Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.

Panelists discuss how to implement and maintain appropriate laboratory monitoring protocols when prescribing oral JAK inhibitors, ensuring patient safety through regular assessment of key clinical parameters.

An expert discusses the detection of circulating tumor DNA (ctDNA) prior to surgery, noting higher detection rates in stage III patients compared with stage IIB/C patients, and its significant association with a greater number of involved lymph nodes, extracapsular extension, and clinically evident disease, while also highlighting that all 6 patients with ctDNA detected during the surveillance period developed recurrent melanoma. The expert also provides an overview of the 40-gene expression profile (GEP) test for squamous cell carcinoma (SCC) risk stratification and discusses its utility.

An expert discusses how an important part of personalized photoprotection is providing instructions to patients on how and when to apply and reapply sunscreen. It is advised that sunscreen be applied 20 to 30 minutes before going outdoors. It is critical for patients to reapply sunscreen every 2 hours or 4 times a day, depending on the length of time the patient is outdoors.

Panelists discuss how clinical experience in diagnosing generalized pustular psoriasis (GPP) requires recognizing its hallmark features of widespread sterile pustules on inflamed skin, distinguishing it from other pustular conditions, and understanding the genetic mutations and triggers that can precipitate this rare but potentially life-threatening form of psoriasis.

Panelists discuss how generalized pustular psoriasis (GPP), while rare, presents with distinctive widespread sterile pustules on erythematous skin, requires prompt medical intervention, and differs significantly from more common plaque psoriasis in its clinical presentation, triggers, and treatment approaches.

An expert discusses the qualities of genetic tests that are most important to clinicians seeking precise and reliable results for melanoma diagnosis and prognosis, and reviews the 31-gene expression profile (GEP) test, highlighting its ability to classify melanoma risk into 1A, 1B, 2A, and 2B, with 1A patients showing higher melanoma-specific survival (MSS) and overall survival (OS), while 1B/2A and 2B classifications serve as independent predictors of MSS and OS, noting that patients who underwent 31-GEP testing had lower mortality compared with untested patients.

An expert discusses the patient demographics and clinical features used in traditional staging and risk classification of melanoma and squamous cell carcinoma (SCC), examining how staging systems from organizations like the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) align in risk classification, the challenges of relying solely on clinical features for prognosis, and the importance of accurate risk staging in guiding treatment decisions for these cancers.

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.

Panelists discuss how IL-17 is a key pro-inflammatory cytokine in plaque psoriasis pathogenesis. It stimulates keratinocyte proliferation, promotes neutrophil recruitment, induces antimicrobial peptides, and up-regulates other inflammatory mediators, creating a self-perpetuating inflammatory cascade in lesional skin.

Panelists discuss how clinicians can interpret and apply the JAK inhibitor class boxed warning to make informed treatment decisions while weighing potential risks against therapeutic benefits for individual patients.

Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.

An expert discusses how dermatologists guide patients in selecting sunscreens based on skin type (fair skin, skin of color, sensitive skin), coexisting conditions, and environmental exposure (blue light, heavy sun). They recommend sun protection factor (SPF) levels and key ingredients and address adherence barriers. Beyond sunscreen, protective clothing, antioxidants, and physical blockers help shield against visible light and infrared radiation.

An expert discusses how oxidative stress accelerates skin aging by damaging cells through free radicals, which form from UV exposure. Antioxidants such as vitamins C and E, niacinamide, and polyphenols counteract this damage. Combining antioxidants with sunscreen enhances protection, reducing free radical formation and optimizing skin health.

An expert discusses a comprehensive review of treatment options for a 32-year-old woman with alopecia areata, covering baricitinib dosing (4 mg initially), monitoring requirements vs ritlecitinib, expected outcomes, and considerations for topical immunotherapy vs JAK inhibitors.